CN104623633A - 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂 - Google Patents

用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂 Download PDF

Info

Publication number
CN104623633A
CN104623633A CN201510010273.9A CN201510010273A CN104623633A CN 104623633 A CN104623633 A CN 104623633A CN 201510010273 A CN201510010273 A CN 201510010273A CN 104623633 A CN104623633 A CN 104623633A
Authority
CN
China
Prior art keywords
days
neuregulin
hours
nrg
egf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510010273.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·卡加诺
A·甘谷利
J·艾希
T·帕利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of CN104623633A publication Critical patent/CN104623633A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201510010273.9A 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂 Pending CN104623633A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
US61/135,171 2008-07-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801360798A Division CN102159236A (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂

Publications (1)

Publication Number Publication Date
CN104623633A true CN104623633A (zh) 2015-05-20

Family

ID=42005671

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201510010273.9A Pending CN104623633A (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
CN2009801360798A Pending CN102159236A (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
CN201710109733.2A Expired - Fee Related CN107019794B (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2009801360798A Pending CN102159236A (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
CN201710109733.2A Expired - Fee Related CN107019794B (zh) 2008-07-17 2009-07-17 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂

Country Status (13)

Country Link
US (5) US20110166068A1 (enExample)
EP (3) EP3338791B1 (enExample)
JP (5) JP5797112B2 (enExample)
CN (3) CN104623633A (enExample)
AU (3) AU2009292216B2 (enExample)
BR (1) BRPI0916442A2 (enExample)
CA (1) CA2731113A1 (enExample)
DK (2) DK2320933T3 (enExample)
ES (2) ES2664394T3 (enExample)
MX (2) MX384378B (enExample)
PL (2) PL3338791T3 (enExample)
RU (4) RU2536938C2 (enExample)
WO (1) WO2010030317A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108778315A (zh) * 2016-04-19 2018-11-09 莱布尼茨研究所-针对老化研究(弗里茨利普曼研究所) 用于治疗和/或预防神经系统肿瘤的神经调节素
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
WO2021052277A1 (zh) * 2019-09-16 2021-03-25 上海泽生科技开发股份有限公司 重组人神经调节蛋白衍生物及其用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5797112B2 (ja) * 2008-07-17 2015-10-21 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
ES2609927T3 (es) 2008-08-15 2017-04-25 Acorda Therapeutics, Inc. Composiciones y métodos para tratamientos durante periodos no agudos después de lesiones neurológicas del SNC
EP2808339B1 (en) * 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
JP5832437B2 (ja) 2009-10-14 2015-12-16 アコーダ セラピューティクス インコーポレイテッド 末梢神経損傷を処置するためのニューレグリンの使用
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
DK3278811T3 (da) * 2012-03-30 2021-03-01 Acorda Therapeutics Inc Anvendelse af ggf2 til behandling af neuropatisk smerte ved peripheral nerveskade
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
EP3610905B1 (en) 2013-05-22 2021-03-31 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN111407882A (zh) * 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
MA42936A (fr) 2015-09-25 2018-08-01 Douglas B Sawyer Procédé de traitement de blessures cardiaques
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
PL203689B1 (pl) 1998-09-25 2009-11-30 Cubist Pharmaceuticals Zastosowanie daptomycyny
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
AU1916301A (en) 1999-11-12 2001-06-06 Children's Medical Center Corporation Methods for administration of therapeutic agents on an antiangiogenic schedule
MXPA02011656A (es) 2000-05-23 2004-07-30 Cenes Pharmaceuticals Inc Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
EP1569689A4 (en) 2002-01-18 2009-08-05 Novartis Vaccines & Diagnostic IL2 / ANTI-HER2-ANTIBODY COMBINATION THERAPY AGAINST CANCER, which is characterized by overexpression of the HER2-RECEPTOR PROTEIN
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2006087420A2 (en) * 2005-02-18 2006-08-24 Orion Corporation A method for treating heart failure
TW200700082A (en) 2005-03-23 2007-01-01 Pfizer Prod Inc Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
WO2007028085A2 (en) 2005-09-02 2007-03-08 Morehouse School Of Medicine Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
AU2006332340B2 (en) 2005-12-30 2013-09-26 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
PL2262527T3 (pl) 2008-02-29 2017-07-31 Acorda Therapeutics, Inc. Kompozycje do osiągania w surowicy pożądanych poziomów glejowego czynnika wzrostu 2
JP5797112B2 (ja) * 2008-07-17 2015-10-21 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP5832437B2 (ja) 2009-10-14 2015-12-16 アコーダ セラピューティクス インコーポレイテッド 末梢神経損傷を処置するためのニューレグリンの使用
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
DK3278811T3 (da) 2012-03-30 2021-03-01 Acorda Therapeutics Inc Anvendelse af ggf2 til behandling af neuropatisk smerte ved peripheral nerveskade

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D HARARI1等: "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor", 《ONCOGENE》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108778315A (zh) * 2016-04-19 2018-11-09 莱布尼茨研究所-针对老化研究(弗里茨利普曼研究所) 用于治疗和/或预防神经系统肿瘤的神经调节素
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
WO2021052277A1 (zh) * 2019-09-16 2021-03-25 上海泽生科技开发股份有限公司 重组人神经调节蛋白衍生物及其用途

Also Published As

Publication number Publication date
PL2320933T3 (pl) 2018-07-31
JP2019196370A (ja) 2019-11-14
EP3338791A1 (en) 2018-06-27
MX2011000696A (es) 2011-07-29
HK1256637A1 (en) 2019-09-27
EP3632459A1 (en) 2020-04-08
JP2015129137A (ja) 2015-07-16
US20130324466A1 (en) 2013-12-05
RU2719199C1 (ru) 2020-04-17
US20200009228A1 (en) 2020-01-09
US9198951B2 (en) 2015-12-01
US11235031B2 (en) 2022-02-01
JP6189879B2 (ja) 2017-08-30
EP2320933A1 (en) 2011-05-18
US20160113999A1 (en) 2016-04-28
ES2763184T3 (es) 2020-05-27
US20180280477A1 (en) 2018-10-04
JP2022023208A (ja) 2022-02-07
RU2020111236A3 (enExample) 2021-09-21
CN102159236A (zh) 2011-08-17
CN107019794A (zh) 2017-08-08
AU2009292216B2 (en) 2015-03-05
WO2010030317A2 (en) 2010-03-18
RU2536938C2 (ru) 2014-12-27
EP2320933A4 (en) 2013-02-27
BRPI0916442A2 (pt) 2018-06-19
PL3338791T3 (pl) 2020-04-30
US9956266B2 (en) 2018-05-01
EP3338791B1 (en) 2019-09-18
AU2017203528A1 (en) 2017-06-15
DK2320933T3 (en) 2018-04-16
RU2014141514A (ru) 2016-05-10
MX384378B (es) 2025-03-14
AU2015202877B2 (en) 2017-03-09
AU2009292216A1 (en) 2010-03-18
RU2020111236A (ru) 2021-09-21
DK3338791T3 (da) 2019-12-16
JP2011528353A (ja) 2011-11-17
JP2017200949A (ja) 2017-11-09
EP2320933B1 (en) 2017-12-27
US20110166068A1 (en) 2011-07-07
AU2015202877A1 (en) 2015-06-18
RU2698090C2 (ru) 2019-08-22
CN107019794B (zh) 2021-03-12
ES2664394T3 (es) 2018-04-19
RU2011105821A (ru) 2012-08-27
JP5797112B2 (ja) 2015-10-21
CA2731113A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
US11235031B2 (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
AU2020204070B2 (en) Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
HK1241715B (zh) 用於治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
HK40015761A (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
HK1256637B (en) Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
HK1241715A1 (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
HK1157181A (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
HK1157181B (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150520